Chikungunya

חזרתי מהודו, ואובחנתי כחולה בצ'יקונגוניה. הסימפטומים כאבי פרקים חזקים מאוד. איך אפשר להקל, (חוץ מתרופות נגד כאבים ו NSAID) תודה

אני ממליץ לך לנסות אנטי וירלי פורץ דרך נגד מחלת הנשיקה ועוד כמה נגיפים. אני מטופל בזה כבר שבוע בגלל סיפור של תשישות כרונית ומצבי מדהים כיום. האתר של המטפל. WWW,RAMIMO.CO.IL

Sunday, 14 February 2010 Observer In Focus New vaccine prevents chikungunya in monkeys, mice ------------------------------------------------- An experimental vaccine provided 100 per cent protection against the mosquito-borne chikungunya virus in primates and mice, offering hope it will work for humans too, a new study found. There is no known vaccine or treatment for the disease, which has infected millions of people in Africa and Asia and can cause debilitating pain and, in extreme cases, death. Researchers say human trials will start within a year or two, and that the discoveries made could lead to vaccines for diseases stemming from other so-called alphaviruses. The discovery comes at a time when global travel and trade, along with climate change, are expanding the habitats of the mosquitos that carry these pathogens. Scientists led by Gary Nagel, Director of the Vaccine Research Center at the US National Institutes of Health in Bethesda, Maryland identified the proteins that give rise to chikungunya. In laboratory experiments, they created a safe variant of these virus-like particles and immunised rhesus macaques, waiting 15 weeks before exposing the animals to the disease. All the monkeys survived. In a second set of experiments, the researchers injected a serum containing the antibodies the monkeys had developed into genetically-modified mice that essentially had no immune system. The rodents were completely protected from what would have otherwise been a deadly dose of the virus. Published online in the journal Nature Medicine, the study showed that the virus had been suppressed to harmless "background levels" in the vaccinated monkeys. The next step is to figure out how to make it compatible for human use. We are in the process of adapting that to a cell line where it could be made and tested in preliminary phase one trials, Nagel said.